



BEW

Express Mail No. EV 462 737 763 US

INFORMATION	Attorney Docket	UCAL-131CON4	
DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(e) Address to: Mail Stop	First Named Inventor	PRUSINER, STANLEY B.	
	Application Number	10/735,454	
	Confirmation No.	2015	
	Filing Date	December 12, 2003	
	Group Art Unit	1616	
Commissioner for Patents	Examiner Name		
P.O. Box 1450 Alexandria, VA 22313-1450		DECYL SULFATE COMPOSITIONS 'ATING PRIONS''	

Sir:

Applicants submit herewith patents and/or publications which may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56. While this Statement may be "material" pursuant to 37 C.F.R. § 1.56, it is not intended to constitute an admission that any patent, publication, or other information referred to therein is "prior art" for this invention unless specifically designated as such. A listing of patents and/or publications is shown on enclosed Form PTO-SB/08A and a copy of each patent and/or publication is also enclosed.

Each item of information contained in the Information Disclosure Statement filed herewith was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement (37 C.F.R. 1.97(e)(1)). A copy of the communication is enclosed for the Examiner's convenience.

The Examiner is requested to make the citations listed on the enclosed PTO-SB/08A of record in this application. Applicants would appreciate the Examiner initialing and returning the initialed copy of form PTO-SB/08A, indicating the references have been considered and made of record herein.

No fee is believed due as this statement is being submitted within three months of the mailing date of the enclosed foreign communication. However, if it is determined that fees are required, the Commissioner is hereby authorized to charge any necessary fees associated with this communication or credit any overpayment to Deposit Account No. 50-0815, Order No. UCAL-131CON4.

Respectfully submitted, BOZICEVIC, FIELD & FRANCIS LLP

Karl Bozicevic, Reg. No. 28,807

Date:

BOZICEVIĆ, FIELD & FRANCIS LLP

200 Middlefield Road, Suite 200

Menlo Park, CA 94025 Telephone: (650) 327-3400 Facsimile: (650) 327-3231

F:\DOCUMENT\UCAL\131con4\Supp IDS.doc

Please type a plus sign (+) inside this box \rightarrow

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons and states spond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known			
				Application Number	10//735,454		
INFORMATION DISCLOSURE			RE	Filing Date	December 12, 2003		
	STATEMENT BY APPLICANT			First Named Inventor	PRUSINER, STANLEY B.		
				Group Art Unit	1616		
(use as many sheets as necessary)				Examiner Name			
Sheet	1	of	1	Attorney Docket Number	UCAL-131CON4		

	U.S. PATENT DOCUMENTS					
Examin er Initials'	Cite No. ¹	U.S. Pat	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS								
	Cite No. ¹	Foreign Patent Documents	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines,			
		Office ³ Number ⁴ Kind Code ⁵ (<i>if known</i>)			Where Relevant Passages or Relevant Figures Appear	T⁵		
III		WO 01/54736 A2	The Regents of the University of California	08-02-2001				
			-					
						<u> </u>		

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS				
Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
	SUPATTAPONE et al., "Elimination of prions by branched polyamines and implications for therapeutics" <i>PNAS</i> 96(25):14529-14534 (December 7, 1999)			
	Cite No. ¹	Cite No. 1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. SUPATTAPONE et al., "Elimination of prions by branched polyamines and implications		

Examiner	Date		_
Signature	Considered		

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.